Zobrazeno 1 - 10
of 186
pro vyhledávání: '"D. Courvoisier"'
Publikováno v:
European Journal of Public Health. 32
Background Resources are essential for mental health. In temporary stressful situations throughout life, people need to use a particular type of resources, their “reserves”, to handle the stress. We do not know whether “reserves” (economic, c
Autor:
L. Fredeau, D. Courvoisier, R. Aït Medhi, S. Oro, E. Mahé, N. Costedoat-Chalumeau, L. Arnaud, C. Francès, A. Mathian, A. Zahir, J.D. Bouaziz, F. Chasset
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 2:A70-A71
Autor:
B. Gilbert, D. Mongin, E. Nham, D. Courvoisier, K. Lauper, C. Laedermann, R. Müller, A. Finckh
Publikováno v:
Annals of the Rheumatic Diseases. 81:472-473
BackgroundManagement guidelines of RA suggest to administer biological or targeted synthetic DMARD (b/tsDMARD) in combination with conventional synthetic DMARD (csDMARD). Limited data exists about the impact of such csDMARD combination therapy (co-th
Autor:
E. Nham, R. Aymon, D. Mongin, S. A. Bergstra, D. Choquette, C. Codreanu, O. Elkayam, K. Hyrich, F. Iannone, N. Inanc, L. Kearsley-Fleet, E. Kristianslund, T. K. Kvien, B. Leeb, G. Lukina, D. Nordström, K. Pavelka, M. Pombo-Suarez, Z. Rotar, M. J. Santos, D. Courvoisier, K. Lauper, A. Finckh
Publikováno v:
Annals of the Rheumatic Diseases. 81:177-178
BackgroundThe recently presented “ORAL Surveillance Study” has suggested increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to a comparator TNF-inhibitor (TNFi). Currently, there is limited real worl
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
R. Aymon, B. Gilbert, D. Mongin, E. Nham, C. Laedermann, R. Müller, K. Lauper, D. Courvoisier, A. Finckh
Publikováno v:
Annals of the Rheumatic Diseases. 81:1053-1053
BackgroundDrug maintenance is a common outcome measure of real world effectiveness studies, because it combines a measure of drug effectiveness and its tolerance / safety. Major hurdles of observational studies are potential selection biases and conf
Publikováno v:
Annals of the Rheumatic Diseases. 81:917.2-918
BackgroundOpportunistic and chronic infections can arise in the context of treatment used for Autoimmune Rheumatic Diseases (ARDs). Although it is recognized that screening procedures and prophylactic measures must be followed, clinical practice is l
Autor:
M. Iudici, D. Mongin, E. Siegert, P. Carreira, J. H. W. Distler, J. Henes, E. Zanatta, E. Hachulla, G. De Luca, C. Souza Muller, M. J. Salvador, J. L. Tandaipan, B. Valdetaro Bianchi, M. De Santis, A. M. Hoffmann-Vold, A. Gabrielli, O. Distler, D. Courvoisier
Publikováno v:
Annals of the Rheumatic Diseases. 81:732.1-732
BackgroundThe use of glucocorticoids (GC) in systemic sclerosis (SSc) is controversial (1). Despite the lack of solid evidence about their efficacy in SSc, GC are prescribed to control musculoskeletal symptoms, or in combination with immunosuppressiv
POS0668 REAL WORLD EFFECTIVENESS OF BARICITINIB IN THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)
Publikováno v:
Annals of the Rheumatic Diseases. 80:577-578
Background:When not responding to conventional synthetic DMARDs (csDMARDs), rheumatoid arthritis (RA) patients may receive biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) including baricitinib (BARI). While BARI has demonstrated e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.